Verona Pharma PLC reports results for the quarter ended in September 30 - Earnings Summary

• Verona Pharma PLC VRNA.OQ reported a quarterly adjusted loss of 56 cents​​ per share for the quarter ended September 30, lower than the same quarter last year, when the company reported EPS of -18 cents. The mean expectation of six analysts for the quarter was for a loss of 50 cents per share. Wall Street expected results to range from -95 cents to -7 cents per share.

• Revenue was $5.62 million​; analysts expected $2.02 million.

• Verona Pharma PLC's reported EPS for the quarter was a loss of 56 cents​.

• The company reported a quarterly loss of $42.96 million.

• Verona Pharma PLC shares had risen by 21.6% this quarter and gained 76.0% so far this year.

FORECAST CHANGES

• The mean earnings estimate of analysts had fallen by about 35.1% in the last three months.​

• In the last 30 days, there have been no earnings estimate revisions by analysts covering the company.

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 8 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

• The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

Wall Street's median 12-month price target for Verona Pharma PLC is 37.50

This summary was machine generated from LSEG data November 4 at 03:29 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)